Cargando…

The risk factors for cytomegalovirus reactivation following stem cell transplantation

OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors as...

Descripción completa

Detalles Bibliográficos
Autores principales: Valadkhani, Bahareh, Kargar, Mona, Ashouri, Asieh, Hadjibabaie, Molouk, Gholami, Kheirollah, Ghavamzadeh, Ardeshir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776549/
https://www.ncbi.nlm.nih.gov/pubmed/26985438
http://dx.doi.org/10.4103/2279-042X.176554
_version_ 1782419161257869312
author Valadkhani, Bahareh
Kargar, Mona
Ashouri, Asieh
Hadjibabaie, Molouk
Gholami, Kheirollah
Ghavamzadeh, Ardeshir
author_facet Valadkhani, Bahareh
Kargar, Mona
Ashouri, Asieh
Hadjibabaie, Molouk
Gholami, Kheirollah
Ghavamzadeh, Ardeshir
author_sort Valadkhani, Bahareh
collection PubMed
description OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors associated with CMV reactivation. METHODS: We retrospectively evaluated the medical records of 126 consecutive patients who underwent allogenic-HSCT from peripheral blood stem cells from August 2011 to February 2013 in Shariati Hospital. We included HSCT patients with 15 years of age or older, who survived at least 100 days after transplantation. CMV reactivation was detected based on the weekly PP65 assessment. Patients with 10 or more positive cells per 50,000 cells were defined as having high-level antigenemia. FINDINGS: From 126 patients which included in this study, 76 were male (60%). CMV antigenemia was documented in 43 patients (34%). The median time to CMV infection was 40 days (range: 3–77) after transplantation. The incidence of high-level antigenemia during the first 100 days following HSCT was 11%. CONCLUSION: We found that the significant risk factor for CMV antigenemia in multivariate analysis was prior graft-versus-host disease (GVHD) experience and higher donor age. For high-level antigenemia, GVHD or duration of its treatment was significant determinant.
format Online
Article
Text
id pubmed-4776549
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47765492016-03-16 The risk factors for cytomegalovirus reactivation following stem cell transplantation Valadkhani, Bahareh Kargar, Mona Ashouri, Asieh Hadjibabaie, Molouk Gholami, Kheirollah Ghavamzadeh, Ardeshir J Res Pharm Pract Clinical Study OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors associated with CMV reactivation. METHODS: We retrospectively evaluated the medical records of 126 consecutive patients who underwent allogenic-HSCT from peripheral blood stem cells from August 2011 to February 2013 in Shariati Hospital. We included HSCT patients with 15 years of age or older, who survived at least 100 days after transplantation. CMV reactivation was detected based on the weekly PP65 assessment. Patients with 10 or more positive cells per 50,000 cells were defined as having high-level antigenemia. FINDINGS: From 126 patients which included in this study, 76 were male (60%). CMV antigenemia was documented in 43 patients (34%). The median time to CMV infection was 40 days (range: 3–77) after transplantation. The incidence of high-level antigenemia during the first 100 days following HSCT was 11%. CONCLUSION: We found that the significant risk factor for CMV antigenemia in multivariate analysis was prior graft-versus-host disease (GVHD) experience and higher donor age. For high-level antigenemia, GVHD or duration of its treatment was significant determinant. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4776549/ /pubmed/26985438 http://dx.doi.org/10.4103/2279-042X.176554 Text en Copyright: © Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Clinical Study
Valadkhani, Bahareh
Kargar, Mona
Ashouri, Asieh
Hadjibabaie, Molouk
Gholami, Kheirollah
Ghavamzadeh, Ardeshir
The risk factors for cytomegalovirus reactivation following stem cell transplantation
title The risk factors for cytomegalovirus reactivation following stem cell transplantation
title_full The risk factors for cytomegalovirus reactivation following stem cell transplantation
title_fullStr The risk factors for cytomegalovirus reactivation following stem cell transplantation
title_full_unstemmed The risk factors for cytomegalovirus reactivation following stem cell transplantation
title_short The risk factors for cytomegalovirus reactivation following stem cell transplantation
title_sort risk factors for cytomegalovirus reactivation following stem cell transplantation
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776549/
https://www.ncbi.nlm.nih.gov/pubmed/26985438
http://dx.doi.org/10.4103/2279-042X.176554
work_keys_str_mv AT valadkhanibahareh theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT kargarmona theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT ashouriasieh theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT hadjibabaiemolouk theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT gholamikheirollah theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT ghavamzadehardeshir theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT valadkhanibahareh riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT kargarmona riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT ashouriasieh riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT hadjibabaiemolouk riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT gholamikheirollah riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation
AT ghavamzadehardeshir riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation